onr:"swepub:oai:DiVA.org:liu-48765"
Search: onr:"swepub:oai:DiVA.org:liu-48765" > Chronomodulated cap...
- 1 of 1
- Previous record
- Next record
- To hitlist
Chronomodulated capecitabine in combination with short-time oxaliplatin : A Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil
-
- Qvortrup, C. (author)
- Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, Odense C 5000, Denmark, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
-
- Yilmaz, M. (author)
- Department of Oncology, Aalborg University Hospital, Aalborg, Denmark
-
- Ogreid, D. (author)
- Department of Oncology, Rogaland Central Hospital, Stavanger, Norway
- show more...
- show less...
- Department of Oncology, Odense University Hospital, Sdr Boulevard 29, Odense C 5000, Denmark, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark Department of Oncology, Aalborg University Hospital, Aalborg, Denmark (creator_code:org_t)
- Elsevier BV, 2008
- 2008
- English.
- In: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 19:6, s. 1154-1159
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Background: Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC). Chronomodulation might reduce toxicity and improve efficacy. Patients and methods: A phase II study examining chronomodulated XELOX30 (XELOX30chron): oxaliplatin: 130 mg/m2 on day 1, as a 30-min infusion between 1 and 3 p.m. Capecitabine: total daily dose of 2000 mg/m2, 20% of the dose between 7 and 9 a.m. and 80% of the dose between 6 and 8 p.m. in patients with mCRC resistant to irinotecan. Seventy-one patients were enrolled. Response rate was 18%, median progression-free survival 5.1 months and median overall survival (OS) 10.2 months. Platelet count and performance status were significantly correlated to OS in multivariate analyses. Neurotoxicity grade 2 and 3 was seen in 25% and 2% of patients, respectively, other grade 3 toxic effects were as follows: nausea 6%, vomiting 3%, diarrhoea 12% (3% experienced grade 4) and palmoplantart erytem 9%. Conclusion: XELOX30chron is a convenient second-line regimen with efficacy and safety profile similar to other oxaliplatin schedules. To further investigate chronomodulated XELOX, we have started a Nordic randomised phase II study comparing XELOX30 and XELOX30chron as first-line therapy in patients with mCRC. © The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Keyword
- Capecitabine
- Chronotherapy
- Metastatic colorectal cancer
- Oxaliplatin
- Short-time infusion
- XELOX
- NATURAL SCIENCES
- NATURVETENSKAP
- MEDICINE
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Annals of Oncology (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Qvortrup, C.
- Yilmaz, M.
- Ogreid, D.
- Berglund, Åke
- Balteskard, L.
- Ploen, J.
- show more...
- Fokstuen, T.
- Starkhammar, Han ...
- Sorbye, H.
- Tveit, K.
- Pfeiffer, P.
- show less...
- Articles in the publication
- Annals of Oncolo ...
- By the university
- Linköping University
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
